Stocks and Investing
Stocks and Investing
Wed, March 1, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Brian Skorney Maintained (SRPT) at Buy with Increased Target to $202 on, Mar 1st, 2023
Brian Skorney of Baird, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $152 to $202 on, Mar 1st, 2023.
Brian has made no other calls on SRPT in the last 4 months.
There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 0 agree with Brian's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Brian
- Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $160 on, Tuesday, February 28th, 2023
- Joseph Schwartz of "SVB Leerink" Reiterated at Buy and Held Target at $160 on, Friday, January 20th, 2023
- Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $160 on, Thursday, December 22nd, 2022
- Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $158 on, Friday, December 16th, 2022
Contributing Sources